#Viralimmunology #Publichealth @WHO classified sublineages of #SARSCoV2 #omicron XBB.1.16 as a variant being monitored and how infectious XBB.1.16 can be compared to XBB.1.5
📌XBB.1, XBB.1.5 & XBB.1.16 are robustly resistant to several anti #SARSCoV2 #antibodies
📌#sotrovimab are the only monoclonal antibodies exhibits antiviral activity against XBB subvariants, incl XBB.1.16 @thelancetinfdis
📌https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00278-5/fulltext#sec1

Excellent and timely data on XBB.1.16 from G2P-Japan!

H/T @SystemsVirology
---
RT @SystemsVirology
Neutralization assay showed that XBB.1.16 is robustly resistant to BA.2 breakthru infection sera (18-fold vs B.1.1) and BA.5 breakthru infection sera (37-fold vs B.1.1). Importantly, XBB.1.16 was sensitive to #sotrovimab, a therapeutic monoclonal antibody (not shown). 5/
https://twitter.com/SystemsVirology/status/1644186063836155905

The "profound and rapid" selection pressure induced by the mAbs is partly to blame; for example, 33.3% of BA.1 and 0% of BA.2 infected patients developed mutations when treated with #sotrovimab. The drug neutralizes the former more efficiently than it does the latter.

What the UK is doing with #Paxlovid #Evushield and #Remdesivir

RT @SGriffin_Lab@twitter.com

My bit on how "living" with COVID disproportionately affects #CEV and why we must understand our therapeutics properly and use them to their best capacity. Prophylaxis means not having to become ill to be treated!
Thanks @Phoebe_Roth@twitter.com
#Evusheld
#Sotrovimab

https://theconversation.com/covid-drugs-the-uks-treatment-and-prevention-options-and-how-vulnerable-people-are-being-forgotten-195415

🐦🔗: https://twitter.com/SGriffin_Lab/status/1605532947943108609

RT @SGriffin_Lab@twitter.com

My bit on how "living" with COVID disproportionately affects #CEV and why we must understand our therapeutics properly and use them to their best capacity. Prophylaxis means not having to become ill to be treated!
Thanks @Phoebe_Roth@twitter.com
#Evusheld
#Sotrovimab

https://theconversation.com/covid-drugs-the-uks-treatment-and-prevention-options-and-how-vulnerable-people-are-being-forgotten-195415

🐦🔗: https://twitter.com/SGriffin_Lab/status/1605532947943108609

RT @SGriffin_Lab@twitter.com

My bit on how "living" with COVID disproportionately affects #CEV and why we must understand our therapeutics properly and use them to their best capacity. Prophylaxis means not having to become ill to be treated!
Thanks @Phoebe_Roth@twitter.com
#Evusheld
#Sotrovimab

https://theconversation.com/covid-drugs-the-uks-treatment-and-prevention-options-and-how-vulnerable-people-are-being-forgotten-195415

🐦🔗: https://twitter.com/SGriffin_Lab/status/1605532947943108609

RT @SGriffin_Lab@twitter.com

My bit on how "living" with COVID disproportionately affects #CEV and why we must understand our therapeutics properly and use them to their best capacity. Prophylaxis means not having to become ill to be treated!
Thanks @Phoebe_Roth@twitter.com
#Evusheld
#Sotrovimab

https://theconversation.com/covid-drugs-the-uks-treatment-and-prevention-options-and-how-vulnerable-people-are-being-forgotten-195415

🐦🔗: https://twitter.com/SGriffin_Lab/status/1605532947943108609

If there were available active monoclonal antibiodies (mAB) against circulating #SARSCoV2 variants, should they be used as monotherapy when treating (immunocompromised) patients with mild #COVID19❓ 🤔

"Predictors of #COVID19 hospitalization after #sotrovimab in hematologic malignancy patients during the BA.1 Omicron surge"

https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac916/6850570

New pre-print out by my team.

Mutations present in BA.2 spike, combined with in vitro data raised the possibility that Sotrovimab would have reduced effectiveness against #sars-cov-2. Our results indicate that there was no increased risk of hospital admission for BA.2 compared to BA.1, among people treated with #sotrovimab

#covid19 #epidemiology

https://www.medrxiv.org/content/10.1101/2022.10.21.22281171v1.full.pdf